Dermatology Advisor

DermatologyAdvisor.com serves as a valuable resource for dermatologists and healthcare professionals, delivering a wealth of practical information and tools to help them make informed decisions for their patients. The goal of Dermatology Advisor is to equip dermatologists and healthcare providers who treat skin and related conditions with up-to-date, relevant educational content that enhances their clinical practice and elevates patient care. The platform also offers practice management tools and continuing education programs, creating a comprehensive digital experience that tackles many challenges faced by dermatology professionals today.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#391826

United States

#169337

Health/Medicine

#1336

Traffic sources

Monthly visitors

Articles

Steqeyma 45mg/0.5mL Single-Dose Vial Option for Pediatric Use Approved

5 days ago | dermatologyadvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved a new presentation of Steqeyma® (ustekinumab-stba), a biosimilar to Stelara® (ustekinumab), for the treatment of pediatric patients aged 6 to 17 years, weighing less than 60kg, with plaque psoriasis or psoriatic arthritis.
Subcutaneous Infliximab Outperforms Combination Therapy for IBD

1 week ago | dermatologyadvisor.com | Jessica Nye

Immunogenicity is more prevalent among individuals who receive subcutaneous (SC) infliximab vs intravenous (IV) infliximab with an immunomodulator combined, according to study results published in Clinical Gastroenterology and Hepatology. Data about whether IV combinatorial or IV infliximab monotherapy is associated with decreased risk for immunogenicity have been conflicting. In addition, an SC infliximab formulation is now available.
Patients With Psoriasis and Low Vitamin D Levels at Risk for CVD, Mortality

1 week ago | dermatologyadvisor.com | Jessica Nye

Higher concentrations of serum 25-hydroxyvitamin D (25[OH]D) are associated with decreased risk for cardiovascular disease (CVD) and mortality among individuals with psoriasis. These findings, from a cohort study, were published in the Journal of the American Academy of Dermatology. Individuals with psoriasis are at increased risk for vitamin D deficiency, CVD, and mortality.
FDA Drug Approval Decisions Expected in July 2025

1 week ago | dermatologyadvisor.com | Diana Ernst

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA) and making a final decision on marketing approval. The typical period for review is 10 months after the drug application has been accepted by the Agency. For drugs that have Priority Review, the review period is reduced to 6 months from the time of application acceptance.
Seborrheic Dermatitis Outcomes Improved With Higher Isotretinoin Doses

2 weeks ago | dermatologyadvisor.com | Ron Goldberg

Better disease control and lower recurrence rates of seborrheic dermatitis (SD) are seen with higher doses vs lower doses of daily isotretinoin, according to study findings published in the Journal of the American Academy of Dermatology. As most first-line therapies for SD only provide temporary relief to patients, systemic therapies such as oral isotretinoin have emerged as a promising treatment option.
Adjuvant Cemiplimab Could Be New Standard of Care for High-Risk CSCC

2 weeks ago | dermatologyadvisor.com | Erin Clancy

Adjuvant cemiplimab can improve disease-free survival (DFS) in patients with cutaneous squamous cell carcinoma (CSCC) who have completed adjuvant radiotherapy and have a high risk of recurrence, according to research presented at the ASCO Annual Meeting 2025.1 “[C]emiplimab is the only systemic therapy to demonstrate a statistically significant and clinically meaningful reduction in disease recurrence as adjuvant therapy for patients at high risk of CSCC recurrence,” said study presenter...
Intervention Reduces Acute Care Use and Costs for Older Patients With Cancer

2 weeks ago | dermatologyadvisor.com | Erin Clancy

A symptom assessment intervention can reduce acute care use and costs for older adults with cancer, according to a study presented at the ASCO Annual Meeting 2025. The study included 416 patients who had newly diagnosed or relapsed cancer, were 75 years of age and older, and were insured by a Medicare Advantage payer partner. The patients’ median age was 82 years, and 41.4% had stage IV disease.
Merkel Cell Carcinoma Incidence, Mortality Has Stabilized in the United States

2 weeks ago | dermatologyadvisor.com | Ron Goldberg

Merkel cell carcinoma (MCC) incidence and mortality have stabilized in the United States (US) in recent years, and improved survival is linked with diagnosis within the last decade, according to study findings published in the Journal of the American Academy of Dermatology. Although MCC is considered a rare cancer, studies have reported sharply rising incidence in the US. As data beyond 2015 is lacking, it is uncertain if that trend continues currently.
Novel Oral Nutraceutical Improves Acne and Skin Health in Women

2 weeks ago | dermatologyadvisor.com | Jessica Nye

Mild to moderate acne and overall skin health may be significantly improved with the use of an oral nutraceutical among women, according to a study published in the Journal of Cosmetic Dermatology. Evidence has been emerging regarding skin benefits associated with certain non-traditional ingredients, but clinical studies regarding the safety and efficacy of these products are still lacking.
May 2025 Recap: Drug Pipeline Updates

2 weeks ago | dermatologyadvisor.com | Steve Duffy

The table below is a review of notable updates that occurred in May 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. DrugPharmacologic ClassProposed IndicationStatusCardiovascular DiseaseAficamten (Cytokinetics)Cardiac myosin inhibitorTreatment of obstructive hypertrophic cardiomyopathy.